Structural analysis of the ErbB-2 receptor using monoclonal antibodies: Implications for receptor signalling

International Journal of Cancer

Volumn 104, Issue 3, 2003, Pages 303-309

  Yip, Yum L ^a,b   Novotny, Jiri ^c   Edwards, Michael ^a   Ward, Robyn L ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

Antibody; Ectodomain structure; Epitope; ErbB 2

Indexed keywords

ARGININE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCINE; LEUCINE; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; ONCOPROTEIN; POLYPEPTIDE; PROTEIN TYROSINE KINASE;

AMINO ACID SEQUENCE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIMERIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOLECULAR MODEL; ONCOGENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; X RAY CRYSTALLOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; BINDING, COMPETITIVE; BREAST NEOPLASMS; COMPUTER SIMULATION; DNA PRIMERS; EPITOPE MAPPING; FEMALE; GENE LIBRARY; GENES, ERBB-1; GLYCINE; HUMANS; IMMUNOBLOTTING; MAP KINASE SIGNALING SYSTEM; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PHOSPHORYLATION; POLYMERASE CHAIN REACTION; PRECIPITIN TESTS; PROTEIN CONFORMATION; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED; TYROSINE;

EID: 0037431430     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10951     Document Type: Article

References (37)

1. Van Zoelen EJ, Stortelers C, Lenferink AE, Van de Poll ML. The EGF domain: requirements for binding to receptors of the ErbB family. Vitam Horm 2000;59:99-131.
2. Earp HS, Dawson TL, Li X, Yu H. Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 1995;35:115-32.
3. Olayioye MA, Neve RM, Lane HA, Hynes NE. New EMBO members' review: the ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19:3159-67.
4. Jorissen RN, Epa VC, Treutlein HR, Garrett TP, Ward CW, Burgess AW. Characterization of a comparative model of the extracellular domain of the epidermal growth factor receptor. Protein Sci 2000;9:310-24.
5. Abe Y, Odaka M, Inagaki F, Lax I, Schlessinger J, Kohda D. Disulfide bond structure of human epidermal growth factor receptor. J Biol Chem 1998;273:11150-7.
6. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-82.
7. Yonemura Y, Ninomiya I, Tsugawa K, Fushida S, Fujimura T, Miyazaki I, Uchibayashi T, Endou Y, Sasaki T. Prognostic significance of c-erbB-2 gene expression in the poorly differentiated type of adenocarcinoma of the stomach. Cancer Detect Prev 1998;22:139-46.
8. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999;447:227-31.
9. Graus-Porta D, Beerli RR, Hynes NE. Single-chain antibody-mediated intracellular retention of ErbB-2 impairs Neu differentiation factor and epidermal growth factor signaling. Mol Cell Biol 1995;15:1182-91.
10. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y, Hynes NE. Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 1995;15:6496-505.
11. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y. A hierarchical network of inter receptor interactions determines signal transduction by Neu differentiation factor/neluregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-87.
12. Karunagaran D. Tzahar E, Beerli RR. Chen XM, Grausporta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. Erbb-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-64.
13. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997;410:83-6.
14. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, Hynes NE. ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol 1998:18:5042-51.
15. Forster MJ. Molecular modelling in structural biology. Micron 2002:33:365-84.
16. Brenner SE. A tour of structural genomics. Nat Rev Genet 2001;2:801-9.
17. Garrett TP, McKem NM. Lou M, Frenkel MJ, Bentley JD, Lovrecz GO, Elleman TC, Cosgrove LJ, Ward CW. Crystal structure of the first three domains of the Type-1 insulin-like growth factor receptor. Nature 1998;394:395-9.
18. Ward CW, Hoyne PA, Flegg RH. Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins 1995:22:141-53.
19. Ullrich A, Bell JR, Chen EY, Herrera R, Petruzzelli LM, Dull TJ, Gray A, Coussens L, Liao YC, Tsubokawa M, et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 1985;313:756-61.
20. Yip YL, Ward RL. Anti-ErbB-2 monoclonal antibodies and ErbB-2-directed vaccines. Cancer Immunol Immunother 2002;50:569-87.
21. Yip YL, Smith G, Koch J, Dubel S, Ward RL. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-erbb-2 monoclonal antibodies: implications for vaccine design. J Immunol 2001;166;5271-8.
22. Fromant M, Blanquet S, Plateau P. Direct random mutagenesis of gene-sized DNA fragments using polymerase chain reaction. Anal Biochem 1995;224:347-53.
23. Hendlich M, Lackner P, Weitckus S, Floeckner H, Froschauer R, Gottsbacher K, Casari G, Sippl MJ. Identification of native protein folds amongst a large number of incorrect models: the calculation of low energy conformations from potentials of mean force. J Mol Biol 1990;216:167-80.
24. Abagyan RA, Totrov MM. Contact area difference (CAD): a robust measure to evaluate accuracy of protein models. J Mol Biol 1997;268:678-85.
25. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J Mol Biol 1998;280:1-9.
26. Davies DR, Cohen GH. Interactions of protein antigens with antibodies. Proc Natl Acad Sci USA 1996;93:7-12.
27. Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth. Proc Natl Acad Sci USA 1991;88:8691-5.
28. Ben-Levy R, Paterson HF, Marshall CJ, Yarden Y. A single autophosphorylation site confers oncogenicity to the Neu/ErbB-2 receptor and enables coupling to the MAP kinase pathway. EMBO J 1994;13:3302-11.
29. Schlessinger J, Ullrich A. Growth factor signaling by receptor tyrosine kinases. Neuron 1992;9:383-91.
30. Klapper LN, Vaisman N, Hurwitz E, Pinkaskramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to Erbb-2/Her2 blocks crosstalk with growth factor receptors. Oncogene 1997;14:2099-109.
31. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 1999;26:60-70.
32. Sosnick TR, Benjamin DC, Novotny J, Seeger PA, Trewhella J. Distances between the antigen-binding sites of three murine antibody subclasses measured using neutron and X-ray scattering. Biochemistry 1992;31:1779-86.
33. Lax I, Mitra AK, Ravera C, Hurwitz DR, Rubinstein M, Ullrich A, Stroud RM, Schlessinger J. Epidermal growth factor (EGF) induces oligomerization of soluble, extracellular, ligand-binding domain of EGF receptor: a low resolution projection structure of the ligand-binding domain. J Biol Chem 1991;266:13828-33.
34. Goetz M, Carlotti C, Bontems F, Dufourc EJ. Evidence for an alphahelix → pi-bulge helicity modulation for the neu/erbB-2 membrane-spanning segment. Biochemistry 2001;40:6534-40.
35. Bell CA, Tynan JA, Hart KC, Meyer AN, Robertson SC, Donoghue DJ. Rotational coupling of the transmembrane and kinase domains of the Neu receptor tyrosine kinase. Mol Biol Cell 2000;11:3589-99.
36. Moriki T, Maruyama H, Maruyama IN. Activation of preformed EGF receptor dimers by ligand-induced rotation of the transmembrane domain. J Mol Biol 2001;311:1011-26.
37. Constantinescu SN, Huang LJ, Nam H, Lodish HF. The erythropoietin receptor cytosolic juxtamembrane domain contains an essential, precisely orieted, hydrophobic motif. Mol Cell 2001;7:377-85.